Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Roomies Collab Deck 4: GI and ENT > Crohn’s > Flashcards

Crohn’s Flashcards

1
Q

Crohn’s is characterised by ______________ areas of the gastro-intestinal wall with inflammation extending through _____________ layers, ________________ and ______________ of the mucosa, and the presence of ____________; affected areas may occur in any part of the gastro-intestinal tract, interspersed with areas of relatively normal tissue.

A

thickened

all

deep ulceration

fissuring

granulomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the different presentations of Crohn’s disease? (3)

A
  1. Recurrent attacks
  2. Acute exacerbations combined with periods of remission
  3. Less active disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the symptoms of Crohn’s disease? (5)

A
  1. Abdominal pain
  2. Diarrhea
  3. Fever
  4. Weight loss
  5. Rectal bleeding

*symptoms depend on site of disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the complications of Crohn’s disease? (8)

A
  1. Intestinal strictures
  2. Abscesses in the wall of the intestine or adjacent structures
  3. Fistulae
  4. Anemia
  5. Malnutrition
  6. Colorectal and small bowel cancers
  7. Growth failure and delayed puberty in children
  8. Osteoporosis and fractures
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the extra-intestinal manifestations of Crohn’s disease? (5)

A
  1. Arthritis
  2. Abnormalities of the joints,
  3. Eyes,
  4. Liver,
  5. And skin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fistulating Crohn’s disease is a complication that involves the formation of a fistula between the intestine and adjacent structures, such as ______________, _____________, and _____________

A

perianal skin

bladder

vagina

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Fistulating Crohn’s disease occurs in about __/__ of patients, mostly when the disease involves the ___________ area.

A

one quarter

ileocolonic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Treatment of Crohn’s is largely directed at the induction and maintenance of ____________ and the ____________.

A

remission

relief of symptoms

*The aims of drug treatment are to reduce symptoms and maintain or improve quality of life, while minimising toxicity related to drugs over both the short and long term

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

In addition to drug treatment, management options for Crohn’s disease include _____________ and attention to nutrition, which plays an important role in supportive care

A

Smoking cessation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Surgery for patients with Crohn’s disease may be considered in certain patients with early disease limited to the _____________ and in ___________ or _____________ active disease

A

distal ileum

severe

chronic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

A ________________, is used to induce remission in patients with a first presentation or a single inflammatory exacerbation of Crohn’s disease in a 12-month period

A

corticosteroid (either prednisolone or methylprednisolone or intravenous hydrocortisone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

A corticosteroid (either prednisolone or methylprednisolone or intravenous hydrocortisone), is used to induce remission in patients with ________________ or ________________ of Crohn’s disease in a 12-month period

A

a first presentation

a single inflammatory exacerbation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

In patients with distal ileal, ileocaecal or right-sided colonic disease, in whom a conventional corticosteroid is unsuitable or contra-indicated, _____________ may be considered

A

budesonide, an inhale CS (less effective but may cause fewer side-effects than other corticosteroids due to limited systemic exposure)

*aminosalicylates are an alternative option in these patients (less effective than a corticosteroid or budesonide but may be preferred because of fewer side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which two drugs are the main aminosalicylates?

A
  1. Sulfasalazine

2. Mesalazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Aminosalicylates and budesonide __________ (are/are not) appropriate for treating severe presentations and exacerbations of Crohn’s.

A

Are NOT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Add on treatment of Crohn’s is prescribed if there are _______ or more inflammatory exacerbations in a 12-month period, or the ____________ dose cannot be reduced

A

two

corticosteroid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which drugs can be used as add-on treatment in Crohn’s disease? (4)

A

*added to budesonide or corticosteroid

First-line:

  1. Azathioprine
  2. Mercaptopurine (unlicensed)

Second-line:
3. MTX

Third-line:
4. Biologics under specialist supervision eg adalimumab and infliximab (TNF-a inhibitors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

In the treatment of Crohn’s disease, ______________ and _____________ can be used as monotherapy or combined with an immunosuppressant although there is uncertainty about the comparative effectiveness and long-term side-effects of therapy

A

Adalimumab

Infliximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Patients who choose not to receive maintenance treatment during remission should be made aware of the symptoms that may suggest a relapse (most frequently _______________, ______________, ____________, and ____________)

A

unintended weight loss

abdominal pain

diarrhoea

general ill-health

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Which drugs are used for the maintenance of remission in patients with Crohn’s? (2)

A
  1. Azathioprine or mercaptopurine (unlicensed) monotherapy
  2. MTX in patients who required MTX to induce remission or who cannot tolerate azathioprine or mercaptopurine for maintenance

**CS or budesonide should NOT be used

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Active treatment of acute Crohn’s should be distinguished from preventing relapse. Where as ______________ are the mainstay of treatment for managing acute flares/inducing remission in Crohn’s, ________________ are preferred for maintenance of remission.

A

Corticosteroids

Azathioprine or mercaptopurine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

_____________ in combination with up to 3 months’ postoperative _____________ [unlicensed indication] should be considered to maintain remission in patients with ileocolonic Crohn’s disease who have had complete macroscopic resection within the previous 3 months

A

Azathioprine

metronidazole

*Azathioprine alone should be considered for patients who cannot tolerate metronidazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

________________, _____________, and ______________ are no longer recommended to maintain remission following surgery for Crohn’s disease due to the lack of clinical efficacy

A

Aminosalicylates

Biologic therapies

Budesonide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

_______________ or _____________ can be used to manage diarrhoea associated with Crohn’s disease in those who do not have colitis

A

Loperamide hydrochloride

codeine phosphate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

______________ is licensed for the relief of diarrhoea associated with Crohn’s disease, esp in patients who have had an ileal resection

A

Colestyramine (binds bile acids in the bowel to prevent reabsorption); in Crohn’s disease, it decreases diarrhea by normalizing the amount of bowel acid in the bowel esp. for patients who have had ileal resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Why is colestyramine useful in patients with Crohn’s disease?

A

Colestyramine binds bile acids in the bowel to prevent reabsorption; in Crohn’s disease, it decreases diarrhea by normalizing the amount of bowel acid in the bowel esp. for patients who have had ileal resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

___________ fistulae are the most common occurrence in patients with fistulating Crohn’s disease

A

Perianal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Is treatment always necessary for perianal fistulae in Crohn’s disease?

A

Not if they are simple or asymptomatic

Treatment is required when fistulae are symptomatic or cause local drainage

*surgery may be required in conjunction with medical therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

______________ or ____________ [unlicensed indications], alone or in combination, can improve symptoms of fistulating Crohn’s disease but complete healing occurs rarely

A

Metronidazole

ciprofloxacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Metronidazole is usually given in the treatment of fistulating Crohn’s disease for 1 month, but no longer than 3 months because of concerns about ______________

A

peripheral neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Metronidazole is usually given in the treatment of fistulating Crohn’s disease for __________, but no longer than ____________ because of concerns about peripheral neuropathy

A

1 month

3 months

32
Q

Either ______________ or ______________ [unlicensed indications] is used to control the inflammation in fistulating Crohn’s disease and they are continued for maintenance.

A

azathioprine

mercaptopurine

33
Q

__________________ is recommended for patients with active fistulating Crohn’s disease who have not responded to conventional therapy (including antibacterials, drainage and immunosuppressive treatments), or who are intolerant of or have contra-indications to conventional therapy

A

Infliximab (TNF-a inhibitor)

*should be used after ensuring that all sepsis is actively draining

34
Q

_______________, _____________, and _____________ insertion may be appropriate in the treatment of fistulating Crohn’s, particularly before infliximab treatment

A

Abscess drainage

fistulotomy

seton

35
Q

_______________, _____________, or _____________ should be continued as maintenance treatment for at least one year in patients who have been treated for fistulating Crohn’s disease

A

Azathioprine

mercaptopurine

infliximab

36
Q

For the management of non-perianal fistulating Crohn’s disease (including entero-gynaecological and enterovesical fistulae) _____________ is the only recommended approach

A

surgery

37
Q

In addition to being used in the acute management of Crohn’s disease, sulfasalazine is also used in the management of _____________ and _______________

A

Ulcerative colitis (acute treatment and maintenance of remission)

RA

38
Q

Sulfasalazine should be prescribed with caution in which patients? (7)

A
  1. Acute porphyrias
  2. G6PD deficiency
  3. History of allergy
  4. History of asthma
  5. Risk of hematological toxicity
  6. Risk of hepatic toxicity
  7. Slow acetylator status
39
Q

What are the common or very common side effects of aminosalicylates (sulfasalazine and mesalazine)? (7)

A
  1. Arthralgia
  2. Cough
  3. GI discomfort, diarrhea, N/V
  4. Leukopenia
  5. Fever
  6. Skin reactions
  7. Dizziness
40
Q

What are the common or very common side effects specific to sulfasalazine? (5)

A
  1. Insomnia
  2. Stomatitis
  3. Altered taste
  4. Tinnitus
  5. Urine abnormalities
41
Q

For patients taking aminosalicylates, a blood count should be performed and the drug stopped immediately if there is suspicion of a _________________.

A

blood dyscrasia; hematological abnormalities usually occur in the first 3-6 months

42
Q

Aminosalicylates are contraindicated in patients with ______________ hypersensitivity

A

Salicylate (ie aspirin)

43
Q

Is sulfasalazine safe to give in pregnancy?

A

Theoretical risk of neonatal hemolysis in the third trimester; adequate folate supplementation should be given

44
Q

Is sulfasalazine safe to take while breastfeeding?

A

Small amount present in milk; theoretical risk of neonatal hemolysis especially in G6PD-deficient infants

45
Q

Can sulfasalazine be given to patients with hepatic and/or renal impairment?

A

Cation in hepatic impairment

Cation in mild-moderate renal impairment due to risk of toxicity including crystalluria; avoid in severe impairment

46
Q

___________ function should be monitored before starting an oral aminosalicylate, at 3 months of treatment, and then annually during treatment.

A

Renal

47
Q

Renal function should be monitored ____________ an oral aminosalicylate, at ________ months of treatment, and then ___________ during treatment.

A

Before starting

3

annually

48
Q

For patients taking sulfasalazine, close monitoring of _______________ is necessary initially, and at monthly intervals during the first 3 months.

A

full blood counts (including differential white cell count and platelet count)

49
Q

For patients taking sulfasalazine, close monitoring of full blood counts (including differential white cell count and platelet count) is necessary ____________, and at __________ intervals during the first ____________.

A

initially

monthly

3 months

50
Q

For patients taking sulfasalazine, ________________ should be performed at monthly intervals for first 3 months

A

Liver function tests

Also renal function baseline, at 3 months, then annually

51
Q

Patients receiving aminosalicylates, and their carers, should be advised to report any ______________, ____________, ___________, ___________, ___________, or __________ that occurs during treatment

A

unexplained bleeding

bruising

purpura

sore throat

fever

malaise

52
Q

What can occur to some patients who wear contact lenses when taking sulfasalazine?

A

Some soft contact lenses may be stained

53
Q

Caution should be used when prescribing sulfasalazine alongside other drugs that may increase the risk of _____________ or ____________

A

Hepatotoxicity (eg azoles, INH)

Myelosuppression (eg biologics)

54
Q

Unlike sulfasalazine, mesalazine is not licensed for the treatment of _____________

A

Crohn’s

Though both are licensed for treatment of ulcerative colitis

55
Q

Mesalazine is contraindicated in patients with _______________ and _______________

A

Blood clotting abnormalities

Salicylate hypersensitivity

56
Q

Side effects specific to mesalazine include…. (5)

A
  1. Cholestasis exacerbated
  2. Drug fever
  3. Flatulence
  4. Nephritis
  5. Constipation
57
Q

Is mesalazine safe to use in pregnancy and breastfeeding?

A

Negligible quantities cross the placenta or present in breast milk (however, monitor breast-fed infants for diarrhea)

58
Q

Can mesalazine be prescribed to patients with hepatic and/or renal impairment?

A

Caution in mild to moderate hepatic and renal impairment (like sulfasalazine, risk of crystalluria in renal disease)

Avoid in severe hepatic or renal impairment

59
Q

Azathioprine is metabolised to _____________

A

mercaptopurine

60
Q

________________ is metabolised to mercaptopurine

A

Azathioprine

61
Q

In addition to being used in the treatment of Crohn’s disease, azathioprine is also indicated in the treatment of ____________, _____________, ______________, _______________, _____________, ______________, _______________, and ____________

A 
UC (acute and maintenance)
RA that has not responded to other DMARDs
Severe SLE and other CTDs
Poly myosotis in cases of CS resistance 
Suppression of transplant rejection 
Severe refractory eczema (unlicensed)
Generalized MG
Other autoimmune conditions
62
Q

Manufacturer advises reduce dose of azathioprine to one-quarter of the usual dose with concurrent use of ______________.

A

allopurinol

63
Q

What are the contraindications to using azathioprine and mercaptopurine?

A

Absent or very low TPMT activity

64
Q

Caution when prescribing azathioprine or mercaptopurine with other drugs that may cause _______________ or increase the risk of _______________

A

Myelosuppression (eg biologics)

Generalized infection (eg live vaccines)

65
Q

What are the common or very common side effects of azathioprine? (5)

A
  1. Bone marrow suppression
  2. Increased risk of infection
  3. Leukopenia
  4. Pancreatitis
  5. Thrombocytopenia
66
Q

Which side effects of azathioprine may require drug withdrawal? (3)

A
  1. Hypersensitivity
  2. Neutropenia and thrombocytopenia
  3. Nausea (although moderate nausea may be managed by using divided doses, taking after food, prescribing antiemetics, or temporarily reducing the dose)
67
Q

Nausea is common early in the course of treatment with azathioprine and usually resolves after a few weeks without an alteration in dose. Moderate nausea can be managed by using _______________, taking doses ______________, prescribing concurrent _______________ or ____________ the dose.

A

divided daily doses

after food

antiemetics

temporarily reducing

68
Q

Patients who are allergic to azathioprine are also allergic to ________________

A

Mercaptopurine

69
Q

Is azathioprine safe to use during pregnancy and breastfeeding?

A

Azathioprine is teratogenic in animal studies and has been reported to cause premature birth, low birth-weight, and spontaneous abortion
HOWEVER, azathioprine should NOT be stopped in patients who are transplant recipients; use should be supervised during pregnancy by specialist

Okay during breastfeeding

70
Q

Is azathioprine safe to use in patients with hepatic and/or renal failure?

A

Caution (increased monitoring) in severe liver impairment; reduce dose

Reduce dose in renal impairment

71
Q

What pre-treatment screening is required for patients taking azathioprine?

A

The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Manufacturer advises consider measuring TPMT activity before starting azathioprine, mercaptopurine, or tioguanine therapy. Seek specialist advice for those with reduced or absent TPMT activity.

72
Q

What are the monitoring requirements for patients taking azathioprine? (2)

A
  1. Monitor for toxicity throughout treatment

2. FBC weekly for the first 4 weeks, then at least every 3 months

73
Q

Blood tests and monitoring for signs of _________________ are essential in long-term treatment of patients taking azathioprine

A

myelosuppression

74
Q

Regarding azathioprine, patients and their carers should be warned to report immediately any signs or symptoms of ________________

A

bone marrow suppression e.g. inexplicable bruising or bleeding, infection

75
Q

Is mercaptopurine safe to use during pregnancy and breastfeeding?

A

Avoid, teratogenic

Discontinue breastfeeding

76
Q

What monitoring requirements are necessary for patients taking mercaptopurine?

A

Monitor liver function

Roomies Collab Deck 4: GI and ENT (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions